Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial)

by on 2 de març de 2026 with No hi ha comentaris
  • Ambrosioni, J., de Lazzari, E., Sánchez-Palomino, S., Bailón, L., Suanzes, P., Busca, C., Ramos-Ruperto, L., Orviz, E., Rivero, Á., Mothe, B., Romero, J. D., Falcó, V., Vicens-Artés, S., Moraga, E., Cruceta, A., Mallolas, J., & Miró, J. M. (2025). Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial). Journal of Infection, 91(5), 106651. https://doi.org/10.1016/j.jinf.2025.106651

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *